Found: 108
Select item for more details and to access through your institution.
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03122-w
- By:
- Publication type:
- Article
Patient-reported burden in adults with atopic dermatitis: an international qualitative study.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03130-w
- By:
- Publication type:
- Article
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 3, p. 485, doi. 10.1007/s40257-024-00853-4
- By:
- Publication type:
- Article
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1145, doi. 10.1007/s13555-024-01158-4
- By:
- Publication type:
- Article
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1211, doi. 10.1007/s13555-024-01155-7
- By:
- Publication type:
- Article
Efficacy of long- term risankizumab treatment for moderate- to- severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 5, p. 864, doi. 10.1111/jdv.19748
- By:
- Publication type:
- Article
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 1007, doi. 10.1007/s13555-024-01147-7
- By:
- Publication type:
- Article
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 2, p. 299, doi. 10.1007/s40257-024-00846-3
- By:
- Publication type:
- Article
Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii3, doi. 10.1093/bjd/ljad498.005
- By:
- Publication type:
- Article
Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii7, doi. 10.1093/bjd/ljad498.009
- By:
- Publication type:
- Article
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii9, doi. 10.1093/bjd/ljad498.012
- By:
- Publication type:
- Article
Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii10, doi. 10.1093/bjd/ljad498.013
- By:
- Publication type:
- Article
Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): Results from cross-sectional analyses of the CorEvitas AD Registry.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii27, doi. 10.1093/bjd/ljad498.030
- By:
- Publication type:
- Article
Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii32, doi. 10.1093/bjd/ljad498.035
- By:
- Publication type:
- Article
Validation of the skin pain numerical rating scale of the Pruritus and Symptoms Assessment for Atopic Dermatitis for adults and adolescents with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii41, doi. 10.1093/bjd/ljad498.043
- By:
- Publication type:
- Article
Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii48, doi. 10.1093/bjd/ljad498.050
- By:
- Publication type:
- Article
Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii66, doi. 10.1093/bjd/ljad498.067
- By:
- Publication type:
- Article
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 2, p. 441, doi. 10.1007/s13555-023-01075-y
- By:
- Publication type:
- Article
Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 2, p. 340, doi. 10.1111/jdv.19500
- By:
- Publication type:
- Article
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies.
- Published in:
- Allergy, 2024, v. 79, n. 1, p. 174, doi. 10.1111/all.15952
- By:
- Publication type:
- Article
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 1, p. 127, doi. 10.1007/s40257-023-00810-7
- By:
- Publication type:
- Article
Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
- Published in:
- Pharmaceutics, 2024, v. 16, n. 1, p. 23, doi. 10.3390/pharmaceutics16010023
- By:
- Publication type:
- Article
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials.
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 4, p. 753, doi. 10.1002/jvc2.203
- By:
- Publication type:
- Article
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 6, p. 939, doi. 10.1007/s40257-023-00806-3
- By:
- Publication type:
- Article
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial.
- Published in:
- Pediatric Dermatology, 2023, v. 40, n. 6, p. 1003, doi. 10.1111/pde.15378
- By:
- Publication type:
- Article
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 4, p. 392, doi. 10.1093/bjd/ljad182
- By:
- Publication type:
- Article
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 1893, doi. 10.1007/s13555-023-00948-6
- By:
- Publication type:
- Article
Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne.
- Published in:
- Journal of Clinical & Aesthetic Dermatology, 2023, v. 16, n. 9, p. 42
- By:
- Publication type:
- Article
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 8, p. 1490, doi. 10.1111/jdv.18926
- By:
- Publication type:
- Article
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 595, doi. 10.1007/s40257-023-00792-6
- By:
- Publication type:
- Article
423 Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.043
- By:
- Publication type:
- Article
388 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.014
- By:
- Publication type:
- Article
373 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.004
- By:
- Publication type:
- Article
403 Achievement of minimal disease activity is associated with improvements in symptoms, quality of life and treatment satisfaction in patients with atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.026
- By:
- Publication type:
- Article
419 Patient satisfaction with treatments for moderate-to-severe atopic dermatitis according to degree and speed of skin and itch improvements: results from a patient survey in the United States.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.039
- By:
- Publication type:
- Article
390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2).
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.016
- By:
- Publication type:
- Article
Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q).
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 2, p. 282, doi. 10.1002/jvc2.126
- By:
- Publication type:
- Article
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
- Published in:
- Pediatric Dermatology, 2023, v. 40, n. 3, p. 452, doi. 10.1111/pde.15283
- By:
- Publication type:
- Article
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 4, p. 867, doi. 10.1007/s13555-023-00905-3
- By:
- Publication type:
- Article
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 4, p. 737, doi. 10.1111/jdv.18851
- By:
- Publication type:
- Article
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 2, p. 305, doi. 10.1007/s40257-022-00739-3
- By:
- Publication type:
- Article
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 3, p. 330, doi. 10.1093/bjd/ljac089
- By:
- Publication type:
- Article
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 7, p. 595, doi. 10.1001/jama.2022.22649
- By:
- Publication type:
- Article
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii6, doi. 10.1093/bjd/ljac140.009
- By:
- Publication type:
- Article
314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii8, doi. 10.1093/bjd/ljac140.011
- By:
- Publication type:
- Article
327 Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii16, doi. 10.1093/bjd/ljac140.022
- By:
- Publication type:
- Article
328 Understanding the impact of atopic dermatitis on patients: a large international, ethnically diverse survey-based qualitative study.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii17, doi. 10.1093/bjd/ljac140.023
- By:
- Publication type:
- Article